XML 47 R14.htm IDEA: XBRL DOCUMENT
v2.4.0.8

LICENSE AGREEMENTS | 6 Months Ended
--- | ---
Jun. 30, 2014
License Agreement [Abstract] |
License Agreement Disclosure [Text Block] | NOTE 7 – LICENSE AGREEMENTS IRAK-4 On June 23, 2014, we entered into an exclusive licensing agreement with Ligand Pharmaceuticals Incorporated ("Ligand") for the development and commercialization of Ligand's interleukin-1 receptor associated kinase-4 ("IRAK-4") inhibitor technology, which currently is in preclinical development for potential use against certain cancers and autoimmune diseases. IRAK-4 is a serine/threonine protein kinase that is a key downstream signaling component of the interleukin-1 receptor and multiple toll-like receptors. Under the terms of the license agreement, Ligand received 125,000 shares of our Common Stock as an upfront license fee. Ligand will also be eligible to receive maximum potential milestone payments of approximately $207 million upon the achievement of specific clinical, regulatory and commercial milestone events. Additionally, Ligand will be entitled to royalties on our future net sales of licensed products containing IRAK-4 inhibitors. The basic royalty rate for licensed products covered by Ligand's issued patents will be 6% for annual sales of up to $1 billion and 9.5% for annual sales in excess of that threshold. In connection with the license agreement, we recognized $1,211,250 of noncash research and development expense during the three months ended June 30, 2014 in connection with the issuance of the above mentioned Common Stock. Additionally, Opus Point Partners, LLC, who identified the opportunity and advised the Company on the transaction, will also be entitled to receive a 1% royalty for annual sales of up to $1 billion. Michael S. Weiss, our Executive Chairman and Interim Chief Executive Officer, is a Managing Member of Opus Point Partners, LLC. TG-1101 In November 2012, we entered into an exclusive (within the territory) sublicense agreement with Ildong relating to the development and commercialization of TG-1101 in South Korea and Southeast Asia. Under the terms of the sublicense agreement, Ildong has been granted a royalty bearing, exclusive right, including the right to grant sublicenses, to develop and commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia, Malaysia, Thailand, Philippines, Vietnam, and Myanmar. An upfront payment of $2,000,000, which was received in December 2012, net of $330,000 of income tax withheld, is being recognized as license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated, and represents the estimated period over which we will have certain ongoing responsibilities under the sublicense agreement. We recorded license revenue of approximately $76,000 for each of the six months ended June 30, 2014 and 2013, and, at June 30, 2014 and December 31, 2013, have deferred revenue of approximately $1,752,381 and $1,829,000, respectively, associated with this $2,000,000 payment (approximately $152,000 of which has been classified in current liabilities at June 30, 2014). We may receive up to an additional $5.0 million in payments upon the achievement of pre-specified milestones. In addition, upon commercialization, Ildong will make royalty payments to us on net sales of TG-1101 in the sublicense territory.

X
- Details
Name: | tgtx_LicenseAgreementAbstract
Namespace Prefix: | tgtx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government. + References No definition available. + Details
Name: | tgtx_LicenseAgreementDisclosureTextBlock
Namespace Prefix: | tgtx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration